Biotechnology Law Report

Papers
(The TQCC of Biotechnology Law Report is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Continuing CRISPR Patent Disputes May Be Usurped by Its Potential Role in Fighting Global Pandemics11
Regulation of Artificial Intelligence in Drug Discovery and Health Care4
Selected Developments in Biotechnology Law and the Biotechnology Industry3
Legal and Ethical Challenges in the Construction of China's Biobanks3
Selected Developments in Biotechnology Law and the Biotechnology Industry3
In Juno v. Kite the Federal Circuit Strikes Down Patent Directed Towards Pioneering Innovation in CAR T-Cell Therapy3
Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines2
Legitimacy of Experimental Use of Patented Research Tools by Chinese Universities2
UK Biotech Corporate Finance Trends Post COVID-192
GlaxoSmithKline v. Teva: Holding a Generic Liable for an Artificial Act of Inducement2
Ferring B.V. v. Allergan, Inc. United States Court of Appeals of the Federal Circuit, 2020 980 F.3d 8411
Par Pharm., Inc. v. Eagle Pharms., Inc.1
Eli Lilly & Co. v. Apotex, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1328, 2020 WL 7490251 (Non-precedential)1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Exclusions from Patentability with an Emphasis on Biotechnological Inventions: A Comparative Study1
Incorrect Translation Causing a Claim to Be Indefinite Under 35 U.S.C. § 112—A Case Study of IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc.1
Horizon Pharma, Inc. v. Dr. Reddy's Labs. Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-1607, 2021 WL 48428 (Non-precedential)1
Observation on the Admission Situation of the Anti-Coronavirus Drug “Remdesivir” in China1
Amgen Inc. v. Sanofi, Aventisub LLC United States Court of Appeals of the Federal Circuit, 2021 987 F.3d 10801
Univ. of Massachusetts v. L'Oreal S.A.1
Dana-Farber Cancer Inst., Inc. v. Ono Pharm. Co. United States Court of Appeals of the Federal Circuit, 2020 964 F.3d 13651
Valeant Pharm. Int'l, Inc. v. Mylan Pharm. Inc. United States Court of Appeals of the Federal Circuit, 2020 955 F.3d 251
The Federal Circuit Continues to Grapple with the Question of Patent Eligibility for Diagnostic Methods1
Hologic, Inc. v. Minerva Surgical, Inc. United States Court of Appeals of the Federal Circuit, 2020 957 F.3d 12561
Verinata Health, Inc. v. Ariosa Diagnostics, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2018-2198, 2020 WL 1970571 (Nonprecedential)1
Eagle Pharm. Inc. v. Slayback Pharma LLC United States Court of Appeals of the Federal Circuit, 2020 958 F.3d 11711
XY, LLC v. Trans Ova Genetics, LC United States Court of Appeals of the Federal Circuit, 2020 968 F.3d 13231
Vectura Ltd. v. Glaxosmithkline LLC. United States Court of Appeals of the Federal Circuit, 2020 981 F.3d 10301
Introduction on Biosafety Law of the People's Republic of China and Linkage Thereof with International and Domestic Regulations1
SawStop Holding LLC v. Vidal United States Court of Appeals of the Federal Circuit, 2022 48 F.4th 13551
Legislative Moves on Biosecurity in China1
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part II1
Novartis Pharms. Corp. v. Accord Healthcare, Inc.1
Juno Therapeutics, Inc. v. Kite Pharma, Inc. United States Court of Appeals of the Federal Circuit, 202110 F.4th 13301
AstraZeneca AB v. Mylan Pharms. Inc.1
Allgenesis Biotherapeutics Inc. v. Cloudbreak Therapeutics, LLC1
Observation on the R&D Effectiveness and Application of China's Novel Coronavirus Vaccine1
Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies1
Bio-Rad Labs., Inc. v. 10X Genomics Inc. United States Court of Appeals of the Federal Circuit, 2020 967 F.3d 13531
State Universities Push the Limits of Eleventh Amendment Sovereign Immunity at the Federal Circuit1
United Therapeutics Corp. v. Liquidia Techs., Inc.1
Myco Indus., Inc. v. BlephEx, LLC United States Court of Appeals of the Federal Circuit, 2020 955 F.3d 11
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Genentech, Inc. v. Immunex Rhode Island Corp. United States Court of Appeals of the Federal Circuit, 2020 964 F.3d 11091
In re Huping Hu United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2104, 2021 WL 1016437 (non-precedential)1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
HIPAA, HIPPA, or HIPPO: What Really Is the Heath Insurance Portability and Accountability Act?1
A Review of Patent Regimes on Health Biotechnology Innovation in India1
The Legislative Paradigm of China's Biosafety Law and Its Positive Significance for the SARS-CoV-2 Prevention and Control1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
14-Day Limit of Human Embryo Research: Moral Issues in the Patent Law in China1
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I1
Idorsia Pharmaceuticals, Ltd. v. Iancu United States Court of Appeals of the Federal Circuit, 2020 811 Fed. Appx. 650 (nonprecedential)1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
The Broad Institute Scores Another Victory in Its Battle with the University of California over the Patenting of CRIPSR1
CareDx, Inc. v. Natera, Inc. United States Court of Appeals of the Federal Circuit, 2022 40 F.4th 13711
Par Pharm., Inc. v. Hospira, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1273, 2020 WL 6846347 (Non-precedential)1
A Look at the Current Status of the CRISPR Patent Interferences Involving Broad Institute, University of California and University of Vienna, ToolGen, and Sigma-Aldrich1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Biogen MA Inc. v. EMD Serono, Inc. United States Court of Appeals of the Federal Circuit, 2020 976 F.3d 13261
Bayer Healthcare LLC v. Baxalta Inc. United States Court of Appeals of the Federal Circuit, 2021 989 F.3d 9641
Biogen Int'l GmbH v. Banner Life Scis. LLC United States Court of Appeals of the Federal Circuit, 2020 956 F.3d 13511
Observation on China's Performance in the Global Supply Chain of COVID-19 Medicine1
Sanofi-Aventis Deutschland GmbH v. Mylan Pharms. Inc.1
0.031483888626099